Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER(+)HER2(−)Rb wild-type and knock-down in breast cancer cell lines

BACKGROUND: Breast cancer (BC) is the second most common type of cancer worldwide. Among targeted therapies for Hormone Receptor-positive (HR(+)) and Human Epidermal growth factor Receptor 2-negative (HER2(−)) BC, the Cyclin-Dependent Kinases (CDK4/6) are targeted by inhibitors such as Ribociclib (R...

Descripción completa

Detalles Bibliográficos
Autores principales: Marinelli, Oliviero, Romagnoli, Emanuela, Maggi, Federica, Nabissi, Massimo, Amantini, Consuelo, Morelli, Maria Beatrice, Santoni, Matteo, Battelli, Nicola, Santoni, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678099/
https://www.ncbi.nlm.nih.gov/pubmed/33213401
http://dx.doi.org/10.1186/s12885-020-07619-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678099/
https://www.ncbi.nlm.nih.gov/pubmed/33213401
http://dx.doi.org/10.1186/s12885-020-07619-1

Ejemplares similares